Autonomix Medical, Inc. (AMIX)
NASDAQ: AMIX · Real-Time Price · USD
3.600
+0.600 (20.00%)
At close: Dec 20, 2024, 4:00 PM
3.550
-0.050 (-1.39%)
After-hours: Dec 20, 2024, 4:03 PM EST
Company Description
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system.
Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
The company develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders.
It has an agreement with NoiseFigure Research, Inc. to develop next generation of its proprietary microchip.
Autonomix Medical, Inc. was incorporated in 2014 and is based in The Woodlands, Texas.
Autonomix Medical, Inc.
Country | United States |
Founded | 2014 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 8 |
CEO | Bradley Hauser |
Contact Details
Address: 21 Waterway Avenue, Suite 300 The Woodlands, Texas 77380 United States | |
Phone | 713 588 6150 |
Website | autonomix.com |
Stock Details
Ticker Symbol | AMIX |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001617867 |
ISIN Number | US05330T1060 |
Employer ID | 47-1607810 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Bradley Hauser | Chief Executive Officer and President |
Walter V. Klemp | Executive Chairman |
Lori H. Bisson | Executive Vice Chairman |
Dr. Robert Schwartz M.D. | Co-Founder and Chief Medical Officer |
Landy Toth | Co-Founder and Chief Technology Officer |
Trent N. Smith CPA | Chief Financial Officer |
Jennifer Cook | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 25, 2024 | 8-K | Current Report |
Nov 25, 2024 | 424B4 | Prospectus |
Nov 22, 2024 | EFFECT | Notice of Effectiveness |
Nov 12, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Nov 12, 2024 | 8-K | Current Report |
Nov 8, 2024 | 10-Q | Quarterly Report |
Nov 4, 2024 | 8-K | Current Report |
Nov 1, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |